ChemoCentryx - CCXI Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last twelve months. There are currently 5 hold ratings, 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CCXI shares.
View CCXI analyst ratings or view top-rated stocks.

8 equities research analysts have issued twelve-month target prices for ChemoCentryx's stock. Their CCXI share price forecasts range from $38.00 to $110.00. On average, they expect the company's stock price to reach $65.25 in the next twelve months. This suggests a possible upside of 26.2% from the stock's current price.
View analysts price targets for CCXI or view top-rated stocks among Wall Street analysts.

ChemoCentryx's stock was trading at $36.41 at the beginning of 2022. Since then, CCXI stock has increased by 42.0% and is now trading at $51.72.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our CCXI earnings forecast.

ChemoCentryx, Inc. (NASDAQ:CCXI) released its quarterly earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, beating analysts' consensus estimates of ($0.45) by $0.13. The biopharmaceutical company had revenue of $17.74 million for the quarter, compared to analyst estimates of $14.70 million. ChemoCentryx had a negative net margin of 357.01% and a negative trailing twelve-month return on equity of 48.52%. During the same quarter in the prior year, the firm earned ($0.35) EPS.

21 employees have rated ChemoCentryx Chief Executive Officer Thomas J. Schall on Glassdoor.com. Thomas J. Schall has an approval rating of 58% among the company's employees. This puts Thomas J. Schall in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 44.0% of employees surveyed would recommend working at ChemoCentryx to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other ChemoCentryx investors own include Exelixis (EXEL), Energy Transfer (ET), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Amicus Therapeutics (FOLD), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Advanced Micro Devices (AMD) and Arrowhead Pharmaceuticals (ARWR).

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

ChemoCentryx's stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (14.96%), State Street Corp (5.67%), Pictet Asset Management SA (3.33%), Northern Trust Corp (0.90%), Integral Health Asset Management LLC (0.81%) and Principal Financial Group Inc. (0.78%). Insiders that own company stock include (International) Ltd Vifor, Geoffrey M Parker, James L Tyree, Markus J Cappel, Pui San Kwan, Susan M Kanaya, Tausif Butt, Thomas A Edwards and Thomas J Schall.
View institutional ownership trends.

Shares of CCXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CCXI stock can currently be purchased for approximately $51.72.

ChemoCentryx (NASDAQ:CCXI) has a market capitalization of $3.69 billion and generates $32.22 million in revenue each year. The biopharmaceutical company earns $-131,760,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis.

The company employs 178 workers across the globe.

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The official website for the company is www.chemocentryx.com. The biopharmaceutical company can be reached via phone at (650) 210-2900, via email at investor@chemocentryx.com, or via fax at 650-210-2910.